इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - enoxaparin sodium 100 mg/ml - solution for injection - enoxaparin - treatment of acute st-segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible or not for subsequent coronary angioplasty.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - pentoxifylline 400 mg - tablets prolonged release - pentoxifylline - for the improvement of blood flow in the peripheral blood vessels.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - ofloxacin 2 mg/ml - solution for infusion - ofloxacin - infections of kidney, urinarty tract, genital organs, respiratory tract, chronic and recurrent ear, nose and throat, skin and soft tissues, bones and joints, bacterial enteritis, abdominal cavity, including pelvis minor and septicemia caused by ofloxacin sensitive microorganisms. prevention of infections in patients with a signifcant reduction of resistance to infections,

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - docetaxel as trihydrate 20 mg / 1 ml - concentrate for solution for infusion - docetaxel - breast cancer: taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - cabazitaxel 60 mg / 1.5 ml - concentrate for solution for infusion - cabazitaxel - in combination with prednisone for the treatment of patients with metastatic hormone refractory prostate cancer (mhrpc) previously treated with a docetaxel-based treatment regimen

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa), oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - buserelin acetate 6.6 mg - rods for implant - buserelin - treatment of advanced hormone - dependent prostatic carcinoma.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - buserelin as acetate 0.1 mg/actuations - solution - buserelin - treatment of advanced hormone dependent prostatic carcinoma. endometriosis. use in ivf. precocious puberty. leyomyoma uteri.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - aflibercept 25 mg/ml - concentrate for solution for infusion - zaltrap, in combination with 5-fluorouracil, leucovorin, irinotecan (folfiri), is indicated for adults with metastatic colorectal cancer (mcrc) that is resistant to or has progressed following an oxaliplatin-containing regimen.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - lixisenatide - solution for injection - lixisenatide 20 mcg / 0.2 ml - lixisenatide - for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.